Value
5.5/10data confidence 83%| Component | Sub-score |
|---|---|
| P/S | 6.4 |
| EV/EBITDA | 0.0 |
| Fwd P/E | 2.3 |
| PEG | 10.0 |
| Analyst target | 9.0 |
- ▸Forward P/E: 49.6x
- ▸PEG: 0.44
CAI · Why this verdict
Why Caris Life Sciences (CAI) is rated HOLD
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictHOLD
Overall score6.3/10
ConfidenceMEDIUM
MacroNEUTRAL
TrendMatrix Research · core thesis
Engine thesis — one sentence
A Rule of 40 score of 90, free cash flow converting at approximately 3x reported net income, a confirmed wide economic moat, and 79% year-over-year revenue growth make this a high-quality growth compounder with analyst-implied upside exceeding 33% and a risk/reward ratio of roughly 4.7-to-1; the key near-term risk is a steep confirmed downtrend and heavy revenue concentration in a single diagnostic platform.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
The company achieves a Rule of 40 score of 90 — an elite level — alongside a return on equity of 28%, a perfect financial strength reading of 9 out of 9, and free cash flow converting at approximately 3x reported net income, collectively describing a high-quality, cash-generative franchise with a confirmed wide economic moat. Quality breakdown | Rule of 40 score remains above 60 over the next 12 months, confirming business quality is sustained even through any near-term growth normalization. | →Stable |
| CounterFree cash flow at 3x net income can reflect non-cash charges or favorable working capital timing rather than permanent structural outperformance; if these items normalize, the exceptional cash quality signal could revert toward net income levels, and a 28% return on equity in an early-stage diagnostics company may reflect a small equity base rather than durable capital efficiency. | ||
Revenue has grown approximately 79% year-over-year, a rate that — if sustained even at a fraction of that pace — suggests the company is in an early market capture phase with significant runway ahead rather than approaching saturation. Growth breakdown | Revenue growth remains above 30% year-over-year for at least 2 consecutive quarters over the next 12 months. | →Stable |
| CounterGrowth at 79% almost certainly benefits from a low base-period comparison; a deceleration toward more sustainable rates is mathematically inevitable, and if that deceleration is more abrupt than consensus assumes, estimates built on elevated growth could be revised sharply lower. | ||
At approximately 33% below the analyst consensus price target with a risk/reward ratio of roughly 4.7-to-1, the current entry offers an unusually attractive payoff structure for a franchise with a confirmed wide economic moat and growth above 70%. Price targets | The share price closes within 10% of the $24 analyst consensus target within 12 months. | →Stable |
| CounterImplied volatility running at approximately 111% signals the market is pricing wide uncertainty around the outcome; in high-growth diagnostics names, analyst targets frequently diverge from realized prices by a substantial margin, and a 4.7-to-1 reward/risk ratio may overstate the certainty of the upside path. | ||
The stock's 200-day moving average has been declining at approximately 8.8% per month, and the share price remains below that declining average — the primary price trend is working materially against any near-term thesis. Momentum breakdown | The 200-day moving average slope turns flat or positive within 3 months, confirming the downtrend is losing momentum. | →Stable |
| CounterVolume accumulation (rising on-balance volume) and improving MACD alongside a momentum score above the passing threshold suggest active buying even as the price remains below its long-term average — if sustained, these short-term signals typically precede a trend reversal rather than confirming further deterioration. | ||
Approximately 84.4% of revenue derives from a single diagnostic platform, creating substantial exposure to competitive disruption, reimbursement changes, or clinical preference shifts affecting that one product line. Bear case | Revenue concentration from the primary platform declines below 70% of total revenue within 18 months as additional products gain commercial scale. | →Stable |
| CounterHigh revenue concentration in a single platform is common and often favorable in the early commercial phase of a diagnostics company; the confirmed wide economic moat may in fact be rooted in that platform's clinical differentiation, making concentration a sign of competitive strength rather than fragility. | ||
The company achieves a Rule of 40 score of 90 — an elite level — alongside a return on equity of 28%, a perfect financial strength reading of 9 out of 9, and free cash flow converting at approximately 3x reported net income, collectively describing a high-quality, cash-generative franchise with a confirmed wide economic moat.
→StableQuality breakdown
- Expectation
- Rule of 40 score remains above 60 over the next 12 months, confirming business quality is sustained even through any near-term growth normalization.
CounterFree cash flow at 3x net income can reflect non-cash charges or favorable working capital timing rather than permanent structural outperformance; if these items normalize, the exceptional cash quality signal could revert toward net income levels, and a 28% return on equity in an early-stage diagnostics company may reflect a small equity base rather than durable capital efficiency.
Revenue has grown approximately 79% year-over-year, a rate that — if sustained even at a fraction of that pace — suggests the company is in an early market capture phase with significant runway ahead rather than approaching saturation.
→StableGrowth breakdown
- Expectation
- Revenue growth remains above 30% year-over-year for at least 2 consecutive quarters over the next 12 months.
CounterGrowth at 79% almost certainly benefits from a low base-period comparison; a deceleration toward more sustainable rates is mathematically inevitable, and if that deceleration is more abrupt than consensus assumes, estimates built on elevated growth could be revised sharply lower.
At approximately 33% below the analyst consensus price target with a risk/reward ratio of roughly 4.7-to-1, the current entry offers an unusually attractive payoff structure for a franchise with a confirmed wide economic moat and growth above 70%.
→StablePrice targets
- Expectation
- The share price closes within 10% of the $24 analyst consensus target within 12 months.
CounterImplied volatility running at approximately 111% signals the market is pricing wide uncertainty around the outcome; in high-growth diagnostics names, analyst targets frequently diverge from realized prices by a substantial margin, and a 4.7-to-1 reward/risk ratio may overstate the certainty of the upside path.
The stock's 200-day moving average has been declining at approximately 8.8% per month, and the share price remains below that declining average — the primary price trend is working materially against any near-term thesis.
→StableMomentum breakdown
- Expectation
- The 200-day moving average slope turns flat or positive within 3 months, confirming the downtrend is losing momentum.
CounterVolume accumulation (rising on-balance volume) and improving MACD alongside a momentum score above the passing threshold suggest active buying even as the price remains below its long-term average — if sustained, these short-term signals typically precede a trend reversal rather than confirming further deterioration.
Approximately 84.4% of revenue derives from a single diagnostic platform, creating substantial exposure to competitive disruption, reimbursement changes, or clinical preference shifts affecting that one product line.
→StableBear case
- Expectation
- Revenue concentration from the primary platform declines below 70% of total revenue within 18 months as additional products gain commercial scale.
CounterHigh revenue concentration in a single platform is common and often favorable in the early commercial phase of a diagnostics company; the confirmed wide economic moat may in fact be rooted in that platform's clinical differentiation, making concentration a sign of competitive strength rather than fragility.
Per-dimension breakdown
Quality
7.2/10data confidence 100%| Component | Sub-score |
|---|---|
| ROE | 9.5 |
| ROA | 6.2 |
| Gross margin | 9.8 |
| Op margin | 1.0 |
| Net margin | 1.9 |
| Current ratio | 6.0 |
| FCF quality | 10.0 |
| Moat | 8.2 |
| Rule of 40 | 9.5 |
| Piotroski F | 10.0 |
- ▸Excellent ROE: 28%
- ▸Excellent cash conversion: 300% FCF/NI
- ▸Wide economic moat
- ▸Compounder quality: strong returns + growth
Growth
10.0/10data confidence 67%| Component | Sub-score |
|---|---|
| Rev growth | 10.0 |
| EPS growth | 10.0 |
- ▸Strong growth: 79% YoY
Momentum
6.2/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 3.7 |
| MACD | 10.0 |
| OBV | 10.0 |
| MA position | 6.0 |
| Volume | 1.4 |
- ▸Volume accumulation (rising OBV)
- ▸Below 200-MA, MA slope -9.9%/30d — confirmed downtrend
Sentiment
6.6/10data confidence 100%| Component | Sub-score |
|---|---|
| Analyst rating | 5.0 |
| Price target | 9.4 |
| erm sentiment | 5.7 |
- ▸Analyst upside: 46%
Insider
5.3/10data confidence 50%| Component | Sub-score |
|---|---|
| materiality | 5.5 |
| holder change | 5.1 |
- ▸Insider buying (low materiality) — $501,426 (0.010% of mkt cap)
Peer rank
5.4/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 6.9 |
| quality rank | 7.1 |
| growth rank | 7.7 |
- ▸Superior ROE vs peers
Technical
0.5/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 0.1 |
| support resistance | 1.5 |
| 52w position | 0.0 |
Risk (lower is worse)
4.6/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 5.3 |
| days to cover | 7.3 |
| volatility | 0.0 |
| put call | 10.0 |
| implied vol | 0.3 |
| max pain risk | 3.0 |
| debt equity | 6.6 |
- ▸High IV: 78%
- ▸Above max pain $5
- ▸Concentration risks: 2 HIGH (10-K Item 1A — sized via position_sizing, validated via buy_confidence)
Catalyst
5.0/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 5.6 |
| earnings timing | 5.0 |
| surprise avg | 4.5 |
How the verdict was assembled
Engine trigger
Maintain position. Not compelling to add more.
Engine technical detail
verdict_path:
L4:PATH_F_HOLDPassed (7)
- MOMENTUM:6.2>=5.5
- ASYMMETRY:1.8>=1.5
- INSIDER:OK
- NEWS_EVENTS:NONE_RECENT
- EARNINGS_PROXIMITY:48d clear
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (0)
none
Warning (2)
- DEATH_CROSS:momentum=6.2>=5.0 recovering
- 8K_FLAG:1.02
Reward-to-Risk
1.80
Upside
+26.9%
Downside
15.0%
Sizing output
AVOID
SetupRECOVERY — Death cross but MACD improving, RSI 63
EdgeNO_EDGE — No clear edge identified
SuitabilityMODERATE — Balanced profile
Investment implication
None of the engine's positive-conviction paths (C-quality, D-momentum) triggered — the F-path HOLD reflects balanced signals. Strongest-cleared gate: MOMENTUM:6.2>=5.5. Top dim: Growth at 10.0; weakest: Technical at 0.5. No conviction either direction.
The strongest dimensions are Growth at 10.0, Quality at 7.2, and Sentiment at 6.6; the weakest are Technical at 0.5, Risk (lower is worse) at 4.6, and Catalyst at 5.0. The V9 engine cleared all gates with 2 warnings, producing an asymmetric reward-to-risk of 1.80 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1The company achieves a Rule of 40 score of 90 — an elite level — alongside a return on equity of 28%, a perfect financial strength reading of 9 out of 9, and free cash flow converting at approximately 3x reported net income, collectively describing a high-quality, cash-generative franchise with a confirmed wide economic moat.
Trip ifRule of 40 score falls below 50 for 2 consecutive reporting periods.
- P2Revenue has grown approximately 79% year-over-year, a rate that — if sustained even at a fraction of that pace — suggests the company is in an early market capture phase with significant runway ahead rather than approaching saturation.
Trip ifRevenue growth decelerates below 30% year-over-year for 2 consecutive quarters.
- P3At approximately 33% below the analyst consensus price target with a risk/reward ratio of roughly 4.7-to-1, the current entry offers an unusually attractive payoff structure for a franchise with a confirmed wide economic moat and growth above 70%.
Trip ifAnalyst consensus price target falls to or below $18.18 (current price), eliminating all analyst-derived upside.
- P4The stock's 200-day moving average has been declining at approximately 8.8% per month, and the share price remains below that declining average — the primary price trend is working materially against any near-term thesis.
Trip ifThe 200-day moving average slope turns positive for 2 consecutive months while the share price holds above that average.
- P5Approximately 84.4% of revenue derives from a single diagnostic platform, creating substantial exposure to competitive disruption, reimbursement changes, or clinical preference shifts affecting that one product line.
Trip ifRevenue concentration in the primary platform falls below 65% of total revenue for 2 consecutive fiscal reporting periods.